Comorbidity status of patients with lung cancer

Abstract

Abstract

Aim: In this study, we aimed to investigate the associations between comorbidity status and age, gender, stage and histopathological type of tumors in patients with lung cancer. Methods: Age, gender, smoking status, stage, accompanying diseases, and histological types of 148 patients were recorded. The Charlson comorbidity index was used for definition and grading of comorbidity. Results: In 44.6% of our patients, there was at least one comorbid disease. When associations between Charlson comorbidity index and demographic variables, smoking status, histological type and stage of the tumor were investigated, following results were found: 45.5 % of men, 46.7% of the smokers, 56.3 % of undifferentiated and 52.6% of patients with squamous cell carcinoma, 48.2% and 49.2 % of widespread and advanced stages of lung cancers, respectively, had medical comorbidities. Conclusions: In our study, medical comorbidity was more common in men than in women, in smoker than in non-smokers, in undifferentiated and squamous cell carcinomas than in the other histological types. The relationship between comorbidity status and stage of the tumor supports the hypothesis of camouflage.

Keywords: Comorbidity, lung cancer, smoking

Özet

Akciğer kanserli hastaların komorbidite durumu

Amaç: Bu çalışmada amacımız akciğer kanseri hastalarında komorbiditenin yaş, cinsiyet, evre ve histopatolojik tipi ile olan ilişkisini incelemekti. Yöntem: Yüz kırk sekiz akciğer kanserli hastanın yaşları, cinsiyetleri, sigara içme durumları,  hastalık evreleri, eşlik eden hastalıkları ve histolojik tipleri kaydedildi. Komorbiditenin tanım ve derecelendirilmesinde Charlson komorbidite indeksi kullanıldı. Bulgular: Hastalarımızın %44,6'sında en az bir komorbid hastalığı vardı. Charlson indeksine göre komorbidite derecesinin cinsiyet, sigara içme durumu, histolojik tip, evre ile olan ilişkisi değerlendirildiğinde erkeklerin %45,5'inde, sigara içme öyküsü olanların %46,7'inde, squamöz hücreli karsinomların %52,6'sında, tiplendirme yapılamayanların 56,3'ünde,  yaygın ve ileri evreye sahip akciğer kanserli olguların sırasıyla %48,2 ve % 49,2'sinde medikal komorbidite tespit edildi. Sonuçlar: Bulgularımıza göre komorbidite, erkeklerde kadınlara göre, sigara içenlerde içmeyenlere göre, tiplendirilmeyen ve skuamöz hücreli karsinomu olanların diğer histolojik tipleri olanlara göre daha fazladır. Hastalarımızın komorbidite ve evre ilişkisi kamuflaj hipotezini desteklemektedir.

Anahtar sözcükler: komorbidite, akciğer kanseri, sigara içme

Keywords

• -

References

1. Spiro SG, Porter JC: Lung cancer-Where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 2002 Nov 1;166(9):1166-96.
2. Parkin GM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
3. Postmus PE. Epidemiology of lung cancer. In: Fishman AP, Elias JA, Fishman JA et al; eds: Fishman’s pulmonary diseases and disorders. New York: McGraw Hill Companies; 1998:1707-19.
4. Ozgun MA, Karagoz B, Bilgi O, Kandemir EG, Turken O. The Prognostic Significance of Comorbidity and Relation of Comorbidity with the Other Prognostic Factors in Patients with Non Small Cell Lung Cancer. International Journal of Hematology and Oncology. 2009;2(19):63–8
5. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and Validation. J Chronic Dis 1987;40(5): 373-83.
6. Sobue T, Suzuki T, Fujimoto I, Doi O, Tateishi R, Sato T. Prognostic factors for surgically treated lung adenocarcinoma patients with special reference to smoking habit. Jpn J Cancer Res 1991;82(1): 33-9.
7. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A Prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 1995 Jan;55(1): 51-6.
8. Tammemagi M, McLaughlin J, Mullen J, Bull SB, Johnson MR, Tsao MS, Casson AG. Study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. Ann Epidemiol 2000 Apr;10(3): 176-85.

9. Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh JWW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study. Lung Cancer 1998 Aug;21(2):105–13.
10. Schrijvers CT, Coebergh JW, Mackenbach JP. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer 1997 Oct;80(8): 1482-8.
11. Mehic B, Zutic H, Mehic A. Profile of Venous Thromboembolism at the Patients with Non-Small Cell Lung Carcinoma. HealthMED 2009;3 (1):3-7.
12. Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: Redefining chronic diseases. Cancer 2000 Feb;88(3): 53-63.
13. Lopez-Encuentra A. Comorbidity in operable lung cancer: A multicenter descriptive study on 2992 patients. Lung Cancer 2002 Mar;35(3): 263-9.
14. Doll R, Peto R, Wheatly K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 1994 Oct 8; 309(6959):901– 11.
15. Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994 Oct 1;74(7suppl):2101–6.
16. McDuffie HH, Klaassen DJ, Dosman JA. Determinants of cell type in patients with cancer of the lungs. Chest 1990 Nov;98(5):1187–93.
17. Siemiatycki J, Krewski D, Franco E, Kaiserman M. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 1995 Jan;24(3):504–14.
18. Margetts BM, Jackson AA. Interactions between people’s diet and their smoking habits: the dietary and nutritional survey of British adults. B MJ 1993 Nov; 307(6916):1381–4.